Amylin Pharmaceuticals, Inc.

Astrazeneca Pharmaceuticals LP

Randaemon Sp. Z O.o.

Krystyna Tatarkiewicz

Bronislava Gedulin

David Geoffrey Parkes

Denis Roy

Jan Jakub Tatarkiewicz

Wieslaw Bohdan Kuzmicz

Janusz Jerzy Borodzinski

Methods are disclosed for manufacturing a true random number generator (TRNG), wherein the TRNG includes a cavity filled with tritium and an electronic sensor constructed to detect energy from the decay of the tritium. One method includes (a) forming the cavity by bonding an enclosing structure to the sensor or adjacent to the sensor such that a portion of the sensor forms an inner surface of the cavity, (b) injecting the tritium gas into the cavity via one or more ports in the enclosing structure, and (c) sealing the one or more ports. Another method includes (a) applying a drop of tritiated water or tritiated gel to a surface of the electronic sensor, and (b) applying epoxy over the drop of tritiated water or tritiated gel (prior to step (b), the surface of the electronic sensor may be cooled sufficiently to freeze the drop of tritiated water or tritiated gel).

Method and apparatus for tritium-based true random number generator

The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.

Method of reducing plasma amylase and/or plasma lipase in patients with pancreatitis

Methods of using GLP-1 receptor agonists to treat pancreatitis

Growing community of inventors

San Diego, CA, United States of America

Krystyna Tatarkiewicz